- According to a New Study, eleven-weekly dose of pullzepatide can lead to significant, substated weight loss for up to 3 years in adults with overweight or obesity who do not have diabetes.
- The Findings Build On Earlier Results from the Surmount-1 trial and suggest that treatment responsibility May Vary Based on Factors Such As Sex and The Complex of Obesity-Related Conditions.
- Refrachers Also Identified Patterns in How Participants Lost Weight Over Time.
To New Study, present at this year the European Congress on Obesity (Eco) In Malaga, Spain (11–14 May) Found That A Once-Weekly Dose of Tirzepatide Can Lead To Signanant and consisting Weight Loss for Up To 3 Years In Adults With Overweight Or Obesity or Obesity diabetes.
The Study Also Suggests That Women and Individuals Without Obesity-Related Health Issues May Respond More Effectively to Tirzepatide (Mounjaro) Therapy.
Refrachers from The University of Padova in Italy, in Collaboration with Eli Lilly and Company, have extended Findings from the Surmount-1 Phase 3 Trial of Tirzepatide. This Secondary Analysis is yet to appeal in A Peer-Reviewed Journal.
The Medication Works by imitating the action of two gut hormones which are release
IT Also AIDS Weight Management by Decreating Appetite, Achieved Through Delaying Stomach Emptying and Activating Brain Regions with GLP-1 RECEPTORS than Signal Satiety.
In 2022, The Surmount-1 trial Showed that adults taking pullzepatide for 72 Weeks Lost, on average, Between 15% and 21% of Their Starting Body Weight, depending on the dose.
UPDATED ANALYSIS SHOWS LASTING WEIGHT LOSS ON TIRZEPATIDE
This updated analysis looks more closely at 700 of those participants.
All participants in This Group were Eithher Living with Obesity (A Body Mass Index, OR BMI, Over 30) Or Were Overweight (BMI of 27 or Higher) and had prediabetes.
The Refrachers Analysed The Average Percountage of Body Weight Lost From The Start of The Trial To Week 176 (Three Years) and Also Measured How Long It Took Participants to Achieve at 20% Reduction In Weight.
Based on This Information, they divided participants into three groups.
They The Looked at How Each Group’s Starting Characteristics Related To Their Weight Loss Patterns and Whether They rear to Plateau.
A Weight Loss Plateau was defined as a journal with Less than at 5% Change in Body Weight Over Three Months Following The Initial Weight Loss, and During All Later Three-Month periods.
The Groups were similar in therms of average Age, How long they had Living With Obesity, Whether They Smoked and Their Starting BMI.
Analysis Reveals 3 Distinct Weight Loss Patterns
Group 1 (248 People) Showed A Steady Rate of Weight Loss, Averaging About at 10% Reduction, and rear Plateau Earlier in the Study.
Group 2 (226 People) Lost Weight More Quickly at The Start (Around 20% of Their Body Weight) Before Hitting A Plateau lateau on.
Group 3 (Also 226 People) Saw the Most Rapid and Substantial Weight Loss, Averaging Around 30%, and Took The Longest Time To Reach A Plateau.
Researchers Explained That Thue in the First Group Maintained An Average Weight Loss of Nearly 10% from Their Starting Body Weight After 3 Years.
In contrast, The Third Group, Characterized by a Higher Proport of Females and Individuals Without Obesity-Related Health Conditions, Achieved An Additional 20% Reduction. This is an overall average weight loss of approximately 31%.
Researchers Found Clear Differences in How Long It Took Each Group To Reach A Weight Loss Plateau by The End Of The Three-Year Treatment.
Most participants in Groups 1 and 2 (About 88%) Had Hit A Plateau by The End of the Study, Compared to Just Over 81% in Group 3.
Among Those Who Did Reach A Plateau, The Timing Varied.
The Majority in Groups 1 and 2 Stopped Losing Weight at Around 24 Weeks into Treatment. In Group 1, About Three-Quarters Had Plateaoued by This Point, and In Group 2, Nearly Half Had.
IN CONTRAST, MOST OF THOSE IN GROUP 3 TOOK LONGER TO REACE A Plateau, With Over 80% OF THEM DOING SO BETWEEN WEEKS 36 AND 48, SHOWING A MORE EXTENDED PERINED PERIOD OF WEIGHT LOSS BEFORE LEVELING OFF.
Weight Loss Plateaous Are Normal, But Benefits Remain
Researchers Explained That Hitting A Weight Loss Plateau is a Natural Part of Any Weight Management Approach, As The Body eventually Activates Mechanisms to Prevent Further Weight Loss.
This is due to the complex interplay of multiple hormones that regulates Appetite and Body Weight and LP-1 and Gip Are Only Two Among Several Involved in This Process.
LEAVE IDENIFYING THREE DISTINTIN PATTERNS IN WEIGHT LOSS OVER TIME, REFOTCHERS NOTED THAT THE MAJORITY OF PARTICIPATIONS WERE ABLE TO MAINTAIN CLINICALLE SIGNANT WEIGHT REDUTION OVER THE THREE-YEAR PERIVERY, REGARDLESS OF FACTOR Obesity, or Their Starting BMI.
They Emphasized that Even Modest Weight Loss, Around 5% of Initial Body Weight, Can Signanantly reduces The Risk of Developing Diabetes and Improve Heart Health by Lowering Blood Pressure and Cholesterol.
Greater Weight Loss, Around 15%, IS LINKED with the Most Substantial Health Improvements.
The Findings, According to Researchers, Could Help Improve Understanding of How Tirzepatide Works Across Different Patient Groups and Support More Personalized Treatment Strategies and Goals.
The Trial Did Not Reveal Any New Safety Concerns, With The Most Frequently Reported Side Effects Being Nausea, Diarrhoea and Constipation.
Three experts, not involved in This Research, Spoke To Medical News Today.
Mir Ali, MD, to Board-Certified General Surgeon, Bariatric Genon and Medical Director of Memorialcare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, Ca, Said That He “Thought This was a good Study Showing ThatSe Méphs Medications Are Ae Very Effective For Substantial Weight Loss. “
“Also, It Showed That Individuals Respond Differently and There Can Be periods of Weight Loss Plateaous. We Also See Weight Loss Plateaous in Surgical Weight Loss Patients,” Ali Added.
However, He noted that “Patients need to be counseled thoroughly on expectations and results.”
“Each Person responds Differently, and it is important to continue the medications long.
– Mir Ali, MD
Jordan Hill, MCD, RD, CSSD AT Live It Up, Pointed Out That “The Surmount-1 3-YEAR Study is Among the First Longitudinal Study to Highlight the Effect of Tirzepatide Treatment on Long-Term Weight Loss in People With Prediabetes.
“Based on the results, it presents a promising treatment solution for meaningful weight loss that is substated on a time,” Hill Added.
“While People replied to the Treatment Differently, There Appears To Be Meaningful Weight Loss Rensass of Pace. Further Research Is Warrad To Understand Any Confounding Factors That Lead To The Differences In Pace of Weight Loss as Well As What Maintenance of The Weight Loss May Like If Subjects Discontinue Treatment look. ”
– Jordan Hill, MCD, RD, CSSD
Ongoing Support and Education Needed to Achieve Benefits
Destini Moody, RD, CSSD, LD, A Registered Dieitian Specializing In Sports Performance, Body Composition Changes and Injury Recovery, Highlights The Importance of Proper Education.
Moody suggestaed that: “People (with) overweight and obesity got where they are likely owned to the nutritional Knowledge. Thus, incese medications will do little for long term Health When Patients Come off the medication of a prescription Proper Education. “
In Summary, Hill Note That “This Research Supports The Idea of Medical Intervention and Therapeutic Approaches to Managing Weight in Those with Prediabetes.”
“It reinforces that meaningful, Substaned Weight Loss May Be Possible With The Right Treatment and creates Opportunities For More Customized Weight Loss and Care Strategies,” Hill Concluded.
